New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
06:22 EDTCVS, HZNP, ESRXHorizon Pharma said Duexis, Vimovo to be placed on CVS, Express exlclusion lists
Horizon Pharma (HZNP) said it has been verbally notified that in August, two pharmacy benefit managers, CVS Caremark (CVS) and Express Scripts (ESRX), expect to announce DUEXIS and VIMOVO will no longer be on their formularies and will be placed on their exclusion lists effective January 1, 2015. As a change in Caremark and ESI formulary status would not take effect until 2015, Horizon Pharma does not expect this potential action to impact the financial guidance of $270M-280M for net revenues and $80M-90M for adjusted EBITDA for fiscal 2014 as provided in first quarter earnings press release dated May 9. In response to potentially being placed on Caremarkís and ESIís exclusion lists, the company said it will immediately accelerate patient and physician focused commercial model to focus prescriptions through other channels such as our Prescriptions Made Easy program, continue working with many of the other PBMs and evaluate price increases. We estimate approximately 20%-30% of DUEXIS and VIMOVO prescriptions could be impacted by the potential actions by Caremark and ESI. In the future, if additional healthcare plans adopt the Caremark or ESI exclusion lists or otherwise exclude DUEXIS or VIMOVO from the formularies they use, which they are not required to do, there could possibly be additional DUEXIS and VIMOVO prescriptions affected.
News For HZNP;CVS;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
07:02 EDTHZNPHorizon announces issuance of additional notice of allowance for Pennsaid 2%
Horizon Pharma announced it received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 14/497,096, entitled "Diclofenac Topical Formulation" that covers Horizon's U.S. approved product PENNSAID 2% w/w. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the ninth U.S. patent to be listed in the Orange Book for PENNSAID 2%.
06:19 EDTHZNPPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 23, 2015
13:16 EDTCVS, ESRXPharmacies, PBMs seen as potential buyers after Omnicare said to explore sale
Subscribe for More Information
12:08 EDTCVS, ESRXLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Larsen, along with Mary Ptacek, VP of Pharmaceutical Strategies Group and Ruth Krystopolski, EVP of Sanford Health, discuss the 2016-2017 Pharmacy Benefit Managers selling season and which PBMs are poised to gain share, the impact of WBAís growth plans, recent M&A activity and biosimilars on an Analyst/Industry conference call to be held on April 24 at 2 pm.
10:13 EDTHZNPHigh option volume stocks
Subscribe for More Information
April 22, 2015
10:28 EDTCVSCVS Health April weekly call activity attributed to takeover chatter
Subscribe for More Information
April 17, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $38 from $31 at Piper Jaffray
Subscribe for More Information
07:11 EDTHZNPHorizon Pharma Q1 results to beat expectations by wide margin, says Stifel
Stifel believes that Horizon Pharma is benefiting from strong prescription trends, and the firm says its view was bolstered by an update on prescriptions that the company gave earlier this week. Stifel raised its price target on the stock to $40 from $30 and keeps a Buy rating on the shares.
07:03 EDTHZNPHorizon Pharma receives Notice of Allowance from USPTO for Pennsaid
Subscribe for More Information
05:51 EDTHZNPStocks with implied volatility movement; ALU HZNP
Subscribe for More Information
April 16, 2015
09:18 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
April 15, 2015
18:51 EDTHZNPHorizon Pharma 15.35M share Secondary priced at $28.25
Subscribe for More Information
11:51 EDTESRXExpress Scripts down 2% as Walgreens speaks at analyst day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use